Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a
leader in cell therapy to treat cancer is aware of the early
release of the abstract entitled “Initial safety, efficacy, and
product attributes from the SURPASS trial with ADPA2M4CD8, a SPEAR
T-cell therapy incorporating an affinity optimized TCR targeting
MAGE-A4 and a CD8α co-receptor” by the Society for the
Immunotherapy of Cancer (“SITC”) Conference.
The full abstract is attached to this release.
The Company will update on the full dose escalation cohort of
the SURPASS trial (6 patients in total) at the virtual SITC
conference on November 11, 2020 at 9 AM EST when posters are made
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR® (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the SEC on August 6, 2020, and our other SEC
filings. The forward-looking statements contained in this press
release speak only as of the date the statements were made and we
do not undertake any obligation to update such forward-looking
statements to reflect subsequent events or
Media Relations:Sébastien Desprez — VP,
Communications and Investor RelationsT: +44 1235 430 583M: +44 7718
Investor Relations:Juli P. Miller, Ph.D. —
Senior Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com SITC Abstract
Title: Initial safety, efficacy, and product
attributes from the SURPASS trial with ADPA2M4CD8, a SPEAR T-cell
therapy incorporating an affinity optimized TCR targeting MAGE-A4
and a CD8α co-receptor
Authors: David S. Hong1, Jeffrey Clarke2,
Tanner Johanns3, Partow Kebriaei1, John V. Heymach1,
Ahmed Galal2, Samuel D. Saibil4, Adrian Sacher4, Francine E.
Brophy5, Gareth Betts6, Natalie Bath6, Will Spinner6,
Alex Tipping6, Jessica Tucci5, Raymond Luke5,
Trupti Trivedi5, Quan Lin5, JeanMarc Navenot5,
Paula M. Fracasso5, Karen Miller6, Elliot Norry5,
Mark Dudley5, Marcus O. Butler4
1The University of Texas MD Anderson Cancer Center, Houston, TX,
United States of America, 2Duke Cancer Center, Durham, NC, United
States of America, 3Washington University School of Medicine, St.
Louis, MO, United States of America,4Princess Margaret Cancer
Centre, Toronto, Ontario, Canada, 5Adaptimmune, Philadelphia, PA,
United States of America, 6Adaptimmune, Abingdon, United
Background: The ongoing SURPASS trial
(NCT04044859) evaluates safety and efficacy of next-generation
ADP-A2M4CD8 SPEAR T-cells co-expressing the CD8α co-receptor with
the engineered MAGE-A4c1032 Tcell receptor (TCR).
Methods: First-in-human trial in HLA-A*02
positive patients (pts) with advanced cancers expressing MAGE-A4
antigen by immunohistochemistry. Eligible pts undergo apheresis,
Tcells are isolated, transduced with a Lentiviral vector containing
the MAGE-A4c1032 TCR and CD8α coreceptor, and expanded. Expansion,
transduction level, cellular composition and function of the
manufactured product (MP) are assessed in vitro. Prior to infusion,
pts receive lymphodepletion with fludarabine 30 mg/m2/day for
4 days and cyclophosphamide 600 mg/m2/day for 3 days.
Results: As of 16 July 2020, 5 pts (1 with
MRCLS, 2 with esophagogastric junction [EGJ] cancers, 1 with
ovarian cancer, and 1 with head and neck cancer) were treated
with ADP-A2M4 CD8 (range ~1 to 5.7 billion transduced cells).
No DLTs or SAEs have been reported. To date, 1 pt with EGJ cancer
had a partial response (PR per RECIST) and has had progression-free
survival >6 months. One pt with head and neck cancer also had a
PR. All other pts have had best overall response of stable
MP expanded by an average of 15.3fold during manufacturing
(range 5.9 to 25.6-fold). On average, 43% of Tcells in the MP
expressed the TCR (range 23 to 63%). The fraction of CD4+ cells in
the final MP varied (range 45 to 84%). Coexpression of the MAGE-A4
TCR and CD8α in CD4+ T-cells in the patient MP enabled CD4+ T-cells
to kill tumor target cells directly in vitro. MAGE-A4 expression in
tumor biopsies varied (H-score range 55 to 300). Transduced T-cells
were detected in peripheral blood of all pts. IFNgamma increased
transiently in the serum of 1 pt who responded.
Conclusions: ADP-A2M4CD8 SPEAR T-cells have
shown an acceptable safety profile and pts with EGJ cancer and head
and neck cancer have demonstrated evidence of antitumor activity.
Translational data and early clinical results indicate that
co-expression of the CD8α co-receptor on CD4+ SPEAR T-cells may
increase the potency of the product by conferring additional
killing activity to the helper T-cell subset. This dose escalation
trial is ongoing and updated clinical and translational data will